Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Pfizer
Neeraj Agarwal; Arun A Azad; Joan Carles; Andre P Fay; Nobuaki Matsubara; Daniel Heinrich; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Nicola Di Santo; Fabian Zohren; Karim Fizazi